Efficacy of Once-Daily Darunavir/Ritonavir 800/100 mg in HIV-Infected, Treatment-Experienced Patients With No Baseline Resistance-Associated Mutations to Darunavir
| Autor: | G. Diego Miralles, Marie-Pierre de Béthune, Tony Vangeneugden, Sabrina Spinosa-Guzman, Sandra De Meyer |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
medicine.medical_specialty Anti-HIV Agents HIV Infections Pharmacology Gastroenterology law.invention Randomized controlled trial law Internal medicine Drug Resistance Viral medicine Humans Pharmacology (medical) Dosing Sida Darunavir Sulfonamides Ritonavir biology business.industry HIV Liter Viral Load biology.organism_classification CD4 Lymphocyte Count Regimen Treatment Outcome Infectious Diseases RNA Viral Drug Therapy Combination Female business Viral load medicine.drug |
| Zdroj: | JAIDS Journal of Acquired Immune Deficiency Syndromes. 49:179-182 |
| ISSN: | 1525-4135 |
| Popis: | Objective: The objective of this study was to examine the potential of once-daily dosing with darunavir/ritonavir 800/100 mg in a HIV-infected, treatment-experienced patient population with no baseline darunavir resistance-associated mutations (RAMs). Methods: Patients in the randomized controlled POWER 1 and 2 trials were treatment experienced, with ≥1 International AIDS Society-USA primary protease inhibitor (PI) mutation. The virological and immunological responses in patients with no baseline darunavir RAMs receiving darunavir/r 800/100 mg once daily (n = 23), darunavir/r 600/100 mg twice daily (n = 29), or currently available PI(s) (n = 28) plus an optimized background regimen were compared. Results: The proportion of patients achieving HIV RNA |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|